| Product Unit Size | Cost | Quantity | Stock |
|---|
Ponatinib is a pan-Bcr-Abl tyrosine kinase inhibitor. It shows efficacy in the treatment of chronic myeloid leukemia (CML) as a second or third line treatment or against Bcr-Abl mutants. It is also an approved treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia, where it specifically targets the Bcr-Abl mutation T315I.
| Cas No. | 943319-70-8 |
|---|---|
| Purity | ≥99% |
| Formula | C29H27F3N6O |
| Formula Wt. | 532.57 |
| Chemical Name | Ponatinib |
| IUPAC Name | 3-(Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl}benzamide |
| Synonym | AP-24534, AP 24534, AP24534, Iclusig |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
O’Hare T., SHakespeare W., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 16(5):401-12 (2009). PMID: 19878872.
Tan F., Putoczki T., et al. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. Onco Targets Ther. 12:1635-645 (2019). PMID: 30705592.
